EXCLUSIVE Woman's colon EXPLODES out of her body after coughing too hard from a cold
Doctors are warning about the dangers of coughing too hard this allergy season.
Earlier this year, doctors wrote a case report of an unnamed woman, 61, from Taiwan, who suffered a rare bowel evisceration - when parts of the intestines protrude outside of the body.
And while rare, similar cases have been reported, like that of an 86-year-old woman from the UK in 2011, who was suffering from a respiratory infection had an intense coughing fit and also experienced evisceration of her small bowel through her vagina.
In both cases, the women experienced the injury because of defects stemming from prior hysterectomies - removal of the uterus.
In the 2025 case report, the woman had undergone a hysterectomy 10 months prior and suffered no complications, but visited the emergency room when she began experiencing abdominal pain.
In an examination, doctors discovered a small part of her bowel was protruding out of her vagina. During emergency surgery to repair the injury doctors discovered a defect in part of her vaginal wall that allowed the intestines to break through and leave her body.
While it was not specified what caused the woman's injury, authors of the case report cite a chronic cough or intense coughing fit as risk factors.
Once the organs were repositioned, the surgeons fixed the defect, the woman recovered and she returned home five days later.
She was formally diagnosed with vaginal cuff dehiscence - the reopening of a surgical site - with small bowel evisceration.
This is a known possible complication of a hysterectomy, but is still very rare, occurring in about 0.032 percent of patients following a pelvic operation.
There is limited data on the occurrence of wound dehiscence, but a 2014 study found up to three-in-100 people who have had abdominal and pelvic surgeries may experience it. That rises to up to 10 percent of elderly patients.
And it can be deadly for four-in-10 patients due to excessive blood loss, prolonged severe pain or injury to the organs that have been exposed.
In the 2011 case report, the woman went to the emergency department and told doctors she had an intense coughing fit and then felt her bowel protruding from her vagina - six inches of her intestines were outside of her body.
For the prior three years, the woman had been experiencing a vaginal vault prolapse - when the top of the vagina falls into the vaginal canal.
The condition had been well-managed, however, by her primary doctor.
Eventually her situation became too complicated and she was referred to a specialist but the evisceration occurred before she was able to make an appointment.
The doctors rushed the woman into surgery where they repaired the defect and replaced her bowels.
The operation was successful and she was discharged six days later.
Officially, the woman's diagnosis was ruptured vaginal vault leading to prolapse of the small bowel.
Authors of the case report wrote the prolapse of small bowel through a ruptured vagina has been reported in just 113 cases worldwide.
The mortality rate in vaginal evisceration is about six percent.
When these injuries occur, they must be treated with surgery to replace the organs and close any open wounds or defects.
A sterile saline covering should also be put on eviscerations to keep the exposed organs moist until surgery can be performed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
42 minutes ago
- Daily Mail
Ozempic-maker's new fat-busting drug cuts body weight by a quarter - and it comes as a jab or a PILL
A new fat-busting drug that is available as a jab or tablet helps patients lose up to a quarter of their body weight, studies suggest. People who received higher doses of amycretin as a weekly injection lost 24.3 per cent of their body weight after 36 weeks of treatment. And those taking daily tablets lost an average of 13.1 per cent of their body weight after 12 weeks, the early stage trials found. Weight loss jabs have been hailed as transformative by NHS leaders. But tablets could be the next big breakthrough in the nation's fight against obesity as they are likely to appeal to a wider audience who are uncomfortable with injecting themselves. An estimated 1.5million Britons use weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out fat jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body—GLP-1 and the amylin receptor. In comparison to amycretin, trials pivotal to getting semaglutide—the ingredient behind Ozempic—approved, show it helped users shed up to 15 per cent of their body weight over 68 weeks. And studies have found rival jab Mounjaro can help obese people lose up to 22.5 per cent of their body weight in 72 weeks. The new amycretin trial involved 125 adults, who took weekly injections of the drug. Those taking the highest dosage (60mg) lost 24.3 per cent after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment, according to findings published in medical journal The Lancet. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1 per cent of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7 per cent, with a third of participants losing 25 per cent or more of their body weight after 72 weeks. GLP-1 injections suffered global shortages after celebrity users sparked a surge in popularity and the NHS has warned people against buying them from unauthorised sources. Professor Sir Stephen Powis, national medical director at NHS England, last week told the NHS ConfedExpo conference in Manchester that weight loss jabs could be doled out as widely as statins if competition in the market brings their price down The country's top doctor warned obesity costs the NHS £11.4billion every year and described the financial burden as 'unsustainable'. From Monday, GPs will be able to prescribe the fat jab mounjaro - also known as tirzepatide - for the first time, in what he labelled an 'exciting milestone'.
The Independent
an hour ago
- The Independent
Weight loss pill set to rival injections after promising studies
A new daily weight loss pill has shown promising results in initial studies. Researchers say amycretin, which can be offered by injection or tablet, helped patients lose a significant amount of weight in the first trials. Those who received higher doses of amycretin as a weekly jab lost 24.3 per cent of their body weight after 36 weeks of treatment, while patients who took daily tablets lost an average of 13.1 per cent of their body weight after 12 weeks. While weight loss jabs have been hailed as transformative by NHS leaders, injections come with additional work for over-stretched health services, so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3 per cent after 36 weeks of treatment. It also showed signs of improving blood sugar levels. Side effects included nausea and vomiting, and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1 per cent of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association 's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7 per cent, with a third of participants losing 25 per cent or more of their body weight after 72 weeks.
Daily Mail
an hour ago
- Daily Mail
Is the controversial suicide capsule coming to Britain? Australian right-to-die campaigner known as 'Dr Death' aims to bring euthanasia pod to the UK
A controversial suicide capsule could be coming to the UK after the assisted dying Bill passed its final Commons vote yesterday. Dr Philip Nitschke, the Australian right-to-die campaigner known as 'Dr Death' who is behind the Sarco euthanasia pod, said he will be 'enthusiastically' seeking to bring the technology to Britain for the first time. The coffin-like device offers patients a way to end their lives painlessly by flooding a sealed chamber with nitrogen gas that leads to loss of consciousness and death within ten minutes. A camera records their final moments and the video is sent to a coroner. Dr Nitschke said he intends to start 'enthusiastically pursuing the option of using the device in the UK' as soon as the assisted dying Bill becomes law. The campaigner said he has already had inquiries from 15 Britons seeking to use the Sarco pod and expects this number to increase with the passing of the Bill. 'We'll be looking to find UK-registered doctors to assist and of course someone who wants to use it and satisfies all of the requirements under the law,' he told The Times. 'The doctors involved would know that this would attract attention and possible close scrutiny, which by and large most doctors aren't enthusiastic about, so we'd have to find someone a little crusading.' If it becomes law, the Terminally Ill Adults (End of Life) Bill will let terminally ill adults in England and Wales with fewer than six months to live apply for an assisted death. The person wishing to die would take an approved substance, provided by a doctor but administered only by the person themselves. So far the Bill does not detail what the medication should be. Last year police made arrests after the Sarco pod was used for the first time by a 64-year-old American woman in Switzerland. Swiss authorities confiscated the capsule and took one of the pod company's founders, Florian Willet, who was present at the death, into custody on suspicion of aiding and abetting suicide. He was detained for ten weeks after police claimed there were strangulation marks on the neck of woman who had died. It comes after MPs on both sides of the assisted dying debate made impassioned interventions ahead of the Commons vote yesterday. Former home secretary Sir James Cleverly opened the debate for opponents of the Bill, speaking movingly of losing his closest friend to cancer this year as he warned that he could have 'lost' these precious final moments had assisted dying been available. Meanwhile Mother of the House Diane Abbott described it as the 'most fateful Bill that we discuss this Parliament'. The Labour MP warned that, under the Bill in its current form, 'there will be people among the most vulnerable and marginalised in our society who lose their lives unnecessarily'. 'It is literally a matter of life and death,' she added. 'I have heard talk today of the injustices of the current situation. What could be more unjust than someone losing their life because of poorly drafted legislation?' Former security minister Tom Tugendhat warned that legalising assisted dying would represent 'a huge shift in the relationship between the individual and the State'. The Tory MP said: 'It's about the power over life and death. Not just over ourselves, because we already have the power to end our own lives, it's called suicide. It is not a crime – it hasn't been a crime in this country for decades. 'This is a different power. This is about the power of the State through its agents to exercise power over life and death. 'Yes, agreed; yes, approved of in advance; but when the State takes a life, even with consent, that is a huge shift in the relationship between the individual and the State.' But one of the Bill's leading backers, Tory MP Kit Malthouse, wanted to give a voice to dying people 'not because they want to be rescued, but because time and time again, they're begging us for mercy'. The former Cabinet minister added: 'We honour life by giving it meaning and power. And the one thing that dying people ask for in their agonising final moments is control over the disease that is destroying them.' Campaigners from both sides had spent the day in rival but respectful demonstrations outside the Houses of Parliament. A cheer erupted as the result was announced on a livestream. Many cried and hugged each other, while others popped champagne. Rebecca Wilcox, Dame Esther Rantzen's daughter, called her mother, who is terminally ill, in front of supporters and told her she wished she was there. Ms Wilcox said that she even gave Bill proponent Kim Leadbeater's mother a 'big hug' following the result announcement and added: 'I don't know whether to have a drink or a really big cry. It was quite extraordinary.' Meanwhile Labour MP Dr Peter Prinsley said: 'As a young doctor, I found the measures that we're debating today completely unconscionable, but now I'm an old doctor, I feel sure this is an essential change.' He added: 'There is an absolute sanctity of human life, but we are not dealing with life or death, rather death or death. For there is also a sanctity of human dignity and fundamental to that is surely choice. Who are we to deny that?'
